

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934

**(Amendment No. 12)\***

**ImmunityBio, Inc.**

---

**(Name of Issuer)**

**Common Stock, par value \$0.0001 per share**

---

**(Title of Class of Securities)**

**45256X103**

---

**(CUSIP Number)**

**Charles Kenworthy**  
**Cambridge Equities, LP, 450 Duley Road**  
**El Segundo, CA, 90245**  
**(310) 836-6400**

**Martin J. Waters**  
**Wilson Sonsini Goodrich & Rosati, 12235 El Camino Real**  
**San Diego, CA, 92130**  
**(858) 350-2300**

---

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**02/23/2026**

---

**(Date of Event Which Requires Filing of This Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

**SCHEDULE 13D**

**CUSIP No. 45256X103**

1 Name of reporting person  
 Cambridge Equities, LP  
 Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
 Source of funds (See Instructions)

4 AF, WC, OO  
 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
 Citizenship or place of organization

6 DELAWARE

7 Sole Voting Power  
 0.00

Number of Shares Beneficially Owned by Each Reporting Person With: 8 Shared Voting Power  
 261,705,814.00

9 Sole Dispositive Power  
 0.00

10 Shared Dispositive Power  
 261,705,814.00

11 Aggregate amount beneficially owned by each reporting person  
 261,705,814.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13 Percent of class represented by amount in Row (11)  
 25.5 %

14 Type of Reporting Person (See Instructions)  
 PN

**Comment for Type of Reporting Person:** The percentage shown in (13) is calculated based upon (x) 261,705,814 shares of the Issuer's Common Stock held by Cambridge Equities, LP ("Cambridge"), divided by (y) 1,028,111,456 shares of the Issuer's Common Stock issued and outstanding, as of February 19, 2026 as provided by the Issuer.

## SCHEDULE 13D

**CUSIP No.** 45256X103

1 Name of reporting person  
 MP 13 Ventures, LLC  
 Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 AF  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE

7 Sole Voting Power

Number of Shares Beneficially Owned by Each Reporting Person With: 0.00  
Shared Voting Power

8 261,705,814.00  
Sole Dispositive Power

9 0.00  
Shared Dispositive Power

10 261,705,814.00  
Aggregate amount beneficially owned by each reporting person

11 261,705,814.00  
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13 25.5 %  
Type of Reporting Person (See Instructions)

14 OO

**Comment for Type of Reporting Person:** The percentage shown in (13) is calculated based upon (x) 261,705,814 shares of the Issuer's Common Stock held by Cambridge, divided by (y) 1,028,111,456 shares of the Issuer's Common Stock issued and outstanding, as of February 19, 2026, as provided by the Issuer. MP 13 Ventures, LLC ("MP 13 Ventures") may be deemed to beneficially own, and share voting power and investment power with Cambridge over, all shares of the Issuer's Common Stock beneficially owned by Cambridge.

## SCHEDULE 13D

**CUSIP No.** 45256X103

1 Name of reporting person  
NantWorks, LLC  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 OO  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

6 Citizenship or place of organization

DELAWARE

Sole Voting Power

7

Number of  
Shares

0.00

Shared Voting Power

Beneficially  
Owned by

8

98,535,253.00

Each  
Reporting  
Person

9

Sole Dispositive Power

With:

0.00

Shared Dispositive Power

10

98,535,253.00

Aggregate amount beneficially owned by each reporting person

11

98,535,253.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12



Percent of class represented by amount in Row (11)

13

9.6 %

Type of Reporting Person (See Instructions)

14

OO

**Comment for Type of Reporting Person:** The percentage shown in (13) is calculated based upon (x) the sum of (i) 9,986,920 shares of the Issuer's Common Stock held by NantWorks, LLC ("NantWorks"); (ii) 8,383,414 shares of the Issuers' Common Stock held by NantBio, Inc. ("NantBio"); (iii) 47,557,934 shares of the Issuer's Common Stock held by NantMobile, LLC ("NantMobile"); and (iv) 32,606,985 shares of the Issuer's Common Stock held by NantCancerStemCell, LLC ("NCSC") divided by (y) 1,028,111,456 shares of the Issuer's Common Stock issued and outstanding, as of February 19, 2026, as provided by the Issuer. NantBio, NantMobile and NCSC are majority-owned subsidiaries of NantWorks, and NantWorks shares voting and dispositive power over the shares beneficially owned by NantBio, NantMobile, and NCSC. NantWorks disclaims beneficial ownership of the shares of the Issuer's Common Stock beneficially owned by NantBio, NantMobile and NCSC, except to the extent of their pecuniary interest.

## SCHEDULE 13D

CUSIP No. 45256X103

Name of reporting person

1

Nant Capital, LLC

Check the appropriate box if a member of a Group (See Instructions)

2



(a)



(b)

3

SEC use only

Source of funds (See Instructions)

4

OO

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5



Citizenship or place of organization

6

DELAWARE

Number of  
Shares  
Beneficially

7

Sole Voting Power

Owned by 0.00  
Each Shared Voting Power  
Reporting 8  
Person 339,465,529.00  
With: Sole Dispositive Power  
9  
0.00  
Shared Dispositive Power  
10  
339,465,529.00

11 Aggregate amount beneficially owned by each reporting person

339,465,529.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Percent of class represented by amount in Row (11)

13 30.3 %

Type of Reporting Person (See Instructions)

14 OO

**Comment for Type of Reporting Person:** The percentage shown in (13) is calculated based upon (x) the sum of (i) 246,412,277 shares of the Issuer's Common Stock held by Nant Capital, LLC ("Nant Capital"); and (ii) 93,053,252 shares of the Issuers' Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of February 19, 2026 pursuant to the conversion of a promissory note divided by (y) the sum of (i) 1,028,111,456 shares of the Issuer's Common Stock issued and outstanding, as of February 19, 2026, as provided by the Issuer; and (ii) 93,053,252 shares of the Issuer's Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of February 19, 2026 pursuant to the conversion of a promissory note.

## SCHEDULE 13D

**CUSIP No.** 45256X103

1 Name of reporting person

California Capital Equity, LLC

Check the appropriate box if a member of a Group (See Instructions)

2  (a)

(b)

3 SEC use only

Source of funds (See Instructions)

4 OO

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Citizenship or place of organization

6 DELAWARE

Number of Shares 7 Sole Voting Power

Beneficially Owned by Each Reporting Person 8 0.00

Shared Voting Power

106,511,412.00

9 Sole Dispositive Power

0.00

Shared Dispositive Power

10

106,511,412.00

Aggregate amount beneficially owned by each reporting person

11

106,511,412.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

10.4 %

Type of Reporting Person (See Instructions)

14

OO

**Comment for Type of Reporting Person:** The percentage shown in (13) is calculated based upon (x) the sum of (i) 7,976,159 shares of the Issuer's Common Stock held by California Capital Equity, LLC ("California Capital"); (ii) 9,986,920 shares of the Issuer's Common Stock held by NantWorks; (iii) 8,383,414 shares of the Issuer's Common Stock held by NantBio; (iv) 47,557,934 shares of the Issuer's Common Stock held by NantMobile; and (v) 32,606,985 shares of the Issuer's Common Stock held by NCSC divided by (y) 1,028,111,456 shares of the Issuer's Common Stock issued and outstanding, as of February 19, 2026, as provided by the Issuer. NantWorks is a wholly-owned subsidiary of California Capital. NantBio, NantMobile and NCSC are majority-owned subsidiaries of NantWorks. California Capital shares voting and dispositive power over the shares beneficially owned by NantWorks, NantBio, NantMobile, and NCSC. California Capital disclaims beneficial ownership of the shares of the Issuer's Common Stock beneficially owned by NantWorks, NantBio, NantMobile and NCSC, except to the extent of their pecuniary interest.

### SCHEDULE 13D

CUSIP No. 45256X103

Name of reporting person

1

Patrick Soon-Shiong

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

AF, PF, OO

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

UNITED STATES

Number of Shares

7

Sole Voting Power

Beneficially Owned by

32,275,375.00

Each Reporting Person

8

Shared Voting Power

713,301,081.00

With:

9

Sole Dispositive Power

32,275,375.00

10 Shared Dispositive Power

713,301,081.00

Aggregate amount beneficially owned by each reporting person

11

745,576,456.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12



Percent of class represented by amount in Row (11)

13

66.3 %

Type of Reporting Person (See Instructions)

14

IN

**Comment for Type of Reporting Person:** The percentage in (13) is calculated based upon (x) the sum of (i) 29,701,752 shares of the Issuer's Common Stock held by Dr. Patrick Soon-Shiong; (ii) 2,459,294 shares of the Issuer's Common Stock that Dr. Soon-Shiong has the right to acquire from the Issuer within 60 days of February 19, 2026 pursuant to the exercise of stock options that were exercisable as of February 19, 2026; (iii) 114,329 shares of the Issuer's Common Stock that Dr. Soon-Shiong has the right to acquire from the Issuer within 60 days of February 19, 2026 pursuant to the vesting of restricted stock units; (iv) 261,705,814 shares of the Issuer's Common Stock held by Cambridge; (v) 7,976,159 shares of the Issuer's Common Stock held by California Capital; (vi) 9,986,920 shares of the Issuer's Common Stock held by NantWorks; (vii) 246,412,277 shares of the Issuer's Common Stock held by Nant Capital; (viii) 93,053,252 shares of the Issuer's Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of February 19, 2026 pursuant to the conversion of a promissory note; (ix) 8,383,414 shares of the Issuer's Common Stock held by NantBio; (x) 47,557,934 shares of the Issuer's Common Stock held by NantMobile; (xi) 32,606,985 shares of the Issuer's Common Stock held by NCSC; and (xii) 5,618,326 shares of the Issuer's Common Stock held by the Chan Soon-Shiong Family Foundation divided by (y) the sum of (i) 1,028,111,456 shares of the Issuer's Common Stock issued and outstanding, as of February 19, 2026, as provided by the Issuer; (ii) 2,459,294 shares of the Issuer's Common Stock that Dr. Soon-Shiong has the right to acquire from the Issuer within 60 days of February 19, 2026 pursuant to the exercise of stock options that were exercisable as of February 19, 2026; (iii) 114,329 shares of the Issuer's Common Stock that Dr. Soon-Shiong has the right to acquire from the Issuer within 60 days of February 19, 2026 pursuant to the vesting of restricted stock units, and (iv) 93,053,252 shares of the Issuer's Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of February 19, 2026, pursuant to the conversion of a promissory note. Dr. Soon-Shiong may be deemed to beneficially own, and share voting power and investment power over, all shares of the Issuer's Common Stock beneficially owned by Cambridge, California Capital, NantWorks, NantBio, NantMobile, NCSC, Nant Capital, and the Chan Soon-Shiong Family Foundation. Dr. Soon-Shiong disclaims beneficial ownership of the shares of the Issuer's Common Stock beneficially owned by Cambridge, California Capital, NantWorks, NantBio, NantMobile, NCSC, Nant Capital, and the Chan Soon-Shiong Family Foundation except to the extent of his pecuniary interest.

## SCHEDULE 13D

### Item 1. Security and Issuer

Title of Class of Securities:

(a)

Common Stock, par value \$0.0001 per share

Name of Issuer:

(b)

ImmunityBio, Inc.

Address of Issuer's Principal Executive Offices:

(c)

3530 John Hopkins Court, San Diego, CALIFORNIA , 92121.

### Item 7. Material to be Filed as Exhibits.

The following documents are filed as exhibits: Exhibit 99.1 Joint Filing Agreement, dated as of September 21, 2023, by and among Cambridge Equities, LP, MP 13 Ventures, LLC, NantWorks, LLC, NantMobile, LLC, Nant Capital, LLC, California Capital Equity, LLC, and Patrick Soon-Shiong (incorporated by reference to Exhibit 99.1 to the Sch 13D/A (Amendment No. 9) filed with the SEC by the Reporting Persons on September 21, 2023). Exhibit 99.2 Nominating Agreement by and between the Issuer and Cambridge Equities, LP, dated June 18, 2015 (incorporated by reference to Exhibit 4.1 to the Issuer's Registration Statement on Form S-1 (File No. 333-205124) filed with the SEC on June 19, 2015). Registration Rights Agreement by and between the Issuer and Cambridge Equities, LP, dated December 23, 2014 (incorporated by reference to Exhibit 4.3 to the Issuer's Registration Statement on Form S-1 (File No. 333-205124) filed with the SEC on June 19, 2015).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Cambridge Equities, LP

Signature: /s/ Charles Kenworthy  
Charles Kenworthy, Manager of MP 13 Ventures,  
Name/Title: LLC, the General Partner of Cambridge Equities,  
LP  
Date: 02/25/2026

MP 13 Ventures, LLC

Signature: /s/ Charles Kenworthy  
Name/Title: Charles Kenworthy, Manager  
Date: 02/25/2026

NantWorks, LLC

Signature: /s/ Robert Morse  
Name/Title: Robert Morse, CFO of NantWorks, LLC  
Date: 02/25/2026

Nant Capital, LLC

Signature: /s/ Charles Kenworthy  
Name/Title: Charles Kenworthy, Manager of Nant Capital,  
LLC  
Date: 02/25/2026

California Capital Equity, LLC

Signature: /s/ Charles Kenworthy  
Name/Title: Charles Kenworthy, Manager of California  
Capital Equity, LLC  
Date: 02/25/2026

Patrick Soon-Shiong

Signature: /s/ Patrick Soon-Shiong  
Name/Title: Patrick Soon-Shiong  
Date: 02/25/2026